Drug Trial Radar · NCT04230473
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 13, 2020
Primary completion
Dec 1, 2020
Study completion Nov 1, 2022
Sponsor
- Lead sponsor
- Juventas Cell Therapy Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory acute lymphoblastic leukemia.
Conditions
- Relapsed or Refractory Acute Lymphoblastic Leukemia
Interventions
single dose of CNCT19Biological
Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT) and Recommended Phase II Dose (RP2D)Time frame: 28 days
- Safety of CNCT19 therapyTime frame: 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.